Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled Hydroxychloroquine in Healthy Adults
NCT04461353Phase 1Completed
- Sponsor
- Pulmoquine Therapeutics, Inc.
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ISPM19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Pulmoquine Therapeutics, Inc. Primary endpoints: Treatment-Emergent Adverse Events, Complete Blood Count at Day 8 and 6 more. Started Jun 2020; status: completed.
02
Drugs
ISPM19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04461353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04461353.